Literature DB >> 20189297

TWEAK/Fn14 promotes apoptosis of human endometrial cancer cells via caspase pathway.

Dengfeng Wang1, Jenny Nga Ting Fung, Ya Tuo, Lina Hu, Chen Chen.   

Abstract

Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor fibroblast growth factor-inducible immediate-early response protein 14 (Fn14) have been detected in several human tumors, and demonstrated to regulate multiple cellular responses, including proliferation, survival, migration, apoptosis and differentiation, suggesting roles in cancer. The objective of this study was to clarify the role of TWEAK/Fn14 in the development of human endometrial cancer. We found that TWEAK gene expression was down-regulated and Fn14 gene expression was up-regulated in human endometrial cancer specimens compared with that in normal endometrial specimens; TWEAK acting on Fn14 decreased cell viability by inducing apoptosis through caspase pathways in endometrial cancer cells. Our results suggest that Fn14 expression is high in endometrial cancers whereas local produced TWEAK may be low. TWEAK/Fn14 pathway activation may promote cancer cell apoptosis, which provides a new therapeutic target for human endometrial cancer treatment. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20189297     DOI: 10.1016/j.canlet.2010.01.027

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  15 in total

1.  Low blood levels of sTWEAK are related to locoregional failure in head and neck cancer.

Authors:  Francesc Xavier Avilés-Jurado; Ximena Terra; David Gómez; Joan Carles Flores; Antoni Raventós; Elsa Maymó-Masip; Xavier León; Vicente Serrano-Gonzalvo; Joan Vendrell; Enric Figuerola; Matilde R Chacón
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-05-26       Impact factor: 2.503

2.  Fn14 receptor promotes invasive potential and metastatic capacity of non-small lung adenocarcinoma cells through the up-regulation of integrin α6.

Authors:  J Jandova; C J Mason; S C Pawar; G S Watts
Journal:  Neoplasma       Date:  2015       Impact factor: 2.575

3.  Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer.

Authors:  Ryo Yoriki; Satoru Akashi; Masayuki Sho; Takeo Nomi; Ichiro Yamato; Kiyohiko Hotta; Tomoyoshi Takayama; Sohei Matsumoto; Kohei Wakatsuki; Kazuhiro Migita; Hideo Yagita; Yoshiyuki Nakajima
Journal:  Exp Ther Med       Date:  2010-12-02       Impact factor: 2.447

4.  Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.

Authors:  Hong Zhou; John W Marks; Walter N Hittelman; Hideo Yagita; Lawrence H Cheung; Michael G Rosenblum; Jeffrey A Winkles
Journal:  Mol Cancer Ther       Date:  2011-05-17       Impact factor: 6.261

5.  HPV Type 16 Infection Switches Keratinocytes from Apoptotic to Proliferative Fate under TWEAK/Fn14 Interaction.

Authors:  Hong Cheng; Na Zhan; Dong Ding; Xiaoming Liu; Xiaoyan Zou; Ke Li; Yumin Xia
Journal:  J Invest Dermatol       Date:  2015-05-27       Impact factor: 8.551

6.  TWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8.

Authors:  Aminah Ikner; Avi Ashkenazi
Journal:  J Biol Chem       Date:  2011-04-27       Impact factor: 5.157

Review 7.  A further TWEAK to multiple sclerosis pathophysiology.

Authors:  Arash Nazeri; Pouria Heydarpour; Shokufeh Sadaghiani; Mohammad Ali Sahraian; Linda C Burkly; Amit Bar-Or
Journal:  Mol Neurobiol       Date:  2013-07-20       Impact factor: 5.590

8.  Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells.

Authors:  Ana Belen Sanz; Maria Dolores Sanchez-Niño; Susana Carrasco; Felix Manzarbeitia; Olga Ruiz-Andres; Rafael Selgas; Marta Ruiz-Ortega; Carmen Gonzalez-Enguita; Jesus Egido; Alberto Ortiz
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

9.  Crystal structure of human TWEAK in complex with the Fab fragment of a neutralizing antibody reveals insights into receptor binding.

Authors:  Alfred Lammens; Monika Baehner; Ulrich Kohnert; Jens Niewoehner; Leopold von Proff; Michael Schraeml; Katja Lammens; Karl-Peter Hopfner
Journal:  PLoS One       Date:  2013-05-08       Impact factor: 3.240

10.  Functional expression of TWEAK and the receptor Fn14 in human malignant ovarian tumors: possible implication for ovarian tumor intervention.

Authors:  Liying Gu; Lan Dai; Cong Cao; Jing Zhu; Chuanwei Ding; Hai-Bo Xu; Lihua Qiu; Wen Di
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.